These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Calcium nephrolithiasis and distal tubular acidosis in type 1 glycogen storage disease. Iida S; Matsuoka K; Inoue M; Tomiyasu K; Noda S Int J Urol; 2003 Jan; 10(1):56-8. PubMed ID: 12534929 [TBL] [Abstract][Full Text] [Related]
44. Stone growth patterns and risk for surgery among children presenting with hypercalciuria, hypocitraturia and cystinuria as underlying metabolic causes of urolithiasis. Zu'bi F; Sidler M; Harvey E; Lopes RI; Hojjat A; Naoum N; Pokarowski M; Lorenzo AJ; Farhat WA; Papanikolaou F; Dos Santos J J Pediatr Urol; 2017 Aug; 13(4):357.e1-357.e7. PubMed ID: 28865885 [TBL] [Abstract][Full Text] [Related]
45. The composition and quantitative analysis of urinary calculi in patients with renal calculi. Jawalekar S; Surve VT; Bhutey AK Nepal Med Coll J; 2010 Sep; 12(3):145-8. PubMed ID: 21446361 [TBL] [Abstract][Full Text] [Related]
46. The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. Favus MJ; Coe FL Scand J Urol Nephrol Suppl; 1980; 53():265-71. PubMed ID: 6938003 [TBL] [Abstract][Full Text] [Related]
47. [Recent advances in the treatment of nephrolithiasis (author's transl)]. Frohmüller H Aktuelle Gerontol; 1979 Dec; 9(12):541-8. PubMed ID: 44817 [TBL] [Abstract][Full Text] [Related]
49. The advances of calcium oxalate calculi associated drugs and targets. Lai Y; Zheng H; Sun X; Lin J; Li Q; Huang H; Hou Y; Zhong H; Zhang D; Fucai T; He Z Eur J Pharmacol; 2022 Nov; 935():175324. PubMed ID: 36257382 [TBL] [Abstract][Full Text] [Related]
50. Stones from bowel disease. Worcester EM Endocrinol Metab Clin North Am; 2002 Dec; 31(4):979-99. PubMed ID: 12474641 [TBL] [Abstract][Full Text] [Related]
51. Directional growth of renal calculi. Hinman F Trans Am Assoc Genitourin Surg; 1978; 70():30-5. PubMed ID: 753019 [TBL] [Abstract][Full Text] [Related]
52. The hyperuricosuric calcium oxalate stone former. Sarig S Miner Electrolyte Metab; 1987; 13(4):251-6. PubMed ID: 3306317 [TBL] [Abstract][Full Text] [Related]
53. [Remarks on the metabolic evaluation of renal lithiasis]. Thomas J J Urol (Paris); 1984; 90(1):1-5. PubMed ID: 6725970 [TBL] [Abstract][Full Text] [Related]
54. Nephrocalcinosis in Calcium Stone Formers Who Do Not have Systemic Disease. Bhojani N; Paonessa JE; Hameed TA; Worcester EM; Evan AP; Coe FL; Borofsky MS; Lingeman JE J Urol; 2015 Nov; 194(5):1308-12. PubMed ID: 25988516 [TBL] [Abstract][Full Text] [Related]
55. [Two cases of uric acid stones unsuccessfully dissociated by oral chemolysis]. Funahashi M; Yamada T; Murayama T Hinyokika Kiyo; 2006 Jan; 52(1):47-8. PubMed ID: 16479990 [TBL] [Abstract][Full Text] [Related]
56. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613 [TBL] [Abstract][Full Text] [Related]
57. Metabolic assessment of recurrent and first renal calcium oxalate stone formers. Çakıroğlu B; Eyyupoğlu E; Hazar AI; Uyanik BS; Nuhoğlu B Arch Ital Urol Androl; 2016 Jul; 88(2):101-5. PubMed ID: 27377084 [TBL] [Abstract][Full Text] [Related]
58. Factors increasing the risk for stone formation in adult patients with cystic fibrosis. Terribile M; Capuano M; Cangiano G; Carnovale V; Ferrara P; Petrarulo M; Marangella M Nephrol Dial Transplant; 2006 Jul; 21(7):1870-5. PubMed ID: 16595587 [TBL] [Abstract][Full Text] [Related]